Cargando…

Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab

Antibody-based immunotherapy is increasingly employed to treat acute lymphoblastic leukemia (ALL) patients. Many T-ALL cells express CD38 on their surface, which can be targeted by the CD38 antibody daratumumab (DARA), approved for the treatment of multiple myeloma. Tumor cell killing by myeloid cel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baumann, Niklas, Arndt, Christian, Petersen, Judith, Lustig, Marta, Rösner, Thies, Klausz, Katja, Kellner, Christian, Bultmann, Miriam, Bastian, Lorenz, Vogiatzi, Fotini, Leusen, Jeanette H. W., Burger, Renate, Schewe, Denis M., Peipp, Matthias, Valerius, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427194/ https://www.ncbi.nlm.nih.gov/pubmed/36052078 http://dx.doi.org/10.3389/fimmu.2022.949140

Ejemplares similares

Enhancement of epidermal growth factor receptor antibody tumor immunotherapy by glutaminyl cyclase inhibition to interfere with CD47/signal regulatory protein alpha interactions
por: Baumann, Niklas, et al.
Publicado: (2021)

Engineering of CD19 Antibodies: A CD19-TRAIL Fusion Construct Specifically Induces Apoptosis in B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Cells In Vivo
por: Winterberg, Dorothee, et al.
Publicado: (2021)

A novel Fc-engineered human ICAM-1/CD54 antibody with potent anti-myeloma activity developed by cellular panning of phage display libraries
por: Klausz, Katja, et al.
Publicado: (2017)

Potent Fc Receptor Signaling by IgA Leads to Superior Killing of Cancer Cells by Neutrophils Compared to IgG
por: Brandsma, Arianne M., et al.
Publicado: (2019)

Fc-engineering significantly improves the recruitment of immune effector cells by anti-ICAM-1 antibody MSH-TP15 for myeloma therapy
por: Klausz, Katja, et al.
Publicado: (2020)

Dual Fc optimization to increase the cytotoxic activity of a CD19-targeting antibody
por: Gehlert, Carina Lynn, et al.
Publicado: (2022)

Enhancing CDC and ADCC of CD19 Antibodies by Combining Fc Protein-Engineering with Fc Glyco-Engineering
por: Roßkopf, Sophia, et al.
Publicado: (2020)

Targeting Myeloid Checkpoint Molecules in Combination With Antibody Therapy: A Novel Anti-Cancer Strategy With IgA Antibodies?
por: Chan, Chilam, et al.
Publicado: (2022)

Corrigendum: Targeting myeloid checkpoint molecules in combination with antibody therapy: A novel anti-cancer strategy with IgA antibodies?
por: Chan, Chilam, et al.
Publicado: (2022)

IgA EGFR antibodies mediate tumour killing in vivo
por: Boross, Peter, et al.
Publicado: (2013)

Effect of a tail piece cysteine deletion on biochemical and functional properties of an epidermal growth factor receptor-directed IgA2 m(1) antibody
por: Brunke, Christina, et al.
Publicado: (2013)

HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity
por: Peipp, Matthias, et al.
Publicado: (2015)

Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells
por: Lustig, Marta, et al.
Publicado: (2023)

Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosis
por: Vogiatzi, Fotini, et al.
Publicado: (2022)

Anti-GD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastoma
por: Evers, Mitchell, et al.
Publicado: (2021)

Novel chimerized IgA CD20 antibodies: Improving neutrophil activation against CD20-positive malignancies
por: Evers, Mitchell, et al.
Publicado: (2020)

Molecular complete remission following combination treatment of daratumumab and venetoclax in an adolescent with relapsed mixed phenotype acute leukemia
por: Stanulla, Martin, et al.
Publicado: (2023)

Sialic Acids on Tumor Cells Modulate IgA Therapy by Neutrophils via Inhibitory Receptors Siglec-7 and Siglec-9
por: Chan, Chilam, et al.
Publicado: (2023)

Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages
por: Zeller, Tobias, et al.
Publicado: (2022)

Perspectives of Fc engineered antibodies in CD19 targeting immunotherapies in pediatric B-cell precursor acute lymphoblastic leukemia
por: Kellner, Christian, et al.
Publicado: (2018)

The novel immunotoxin HM1.24-ETA′ induces apoptosis in multiple myeloma cells
por: Staudinger, M, et al.
Publicado: (2014)

Specific Targeting of Lymphoma Cells Using Semisynthetic Anti-Idiotype Shark Antibodies
por: Macarrón Palacios, Arturo, et al.
Publicado: (2020)

Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells
por: Lutz, Sebastian, et al.
Publicado: (2023)

Preclinical Evidence for the Efficacy of CD79b Immunotherapy in B-cell Precursor Acute Lymphoblastic Leukemia
por: Lenk, Lennart, et al.
Publicado: (2022)

Fc Engineering Strategies to Advance IgA Antibodies as Therapeutic Agents
por: van Tetering, Geert, et al.
Publicado: (2020)

Promoting natural killer cell functions by recombinant immunoligands mimicking an induced self phenotype
por: Kellner, Christian, et al.
Publicado: (2013)

Balancing the CD38 Expression on Effector and Target Cells in Daratumumab-Mediated NK Cell ADCC against Multiple Myeloma
por: Lejeune, Margaux, et al.
Publicado: (2021)

Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting
por: Meyer, Saskia, et al.
Publicado: (2015)

Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma
por: Afrough, Aimaz, et al.
Publicado: (2023)

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
por: Frerichs, Kristine A., et al.
Publicado: (2021)

AP-1 Transcription Factor Complex Members FOSB and FOS are Linked With CNS Infiltration and Inferior Prognosis in Childhood T-ALL
por: Spory, Lea, et al.
Publicado: (2023)

Focal Seizures and Posterior Reversible Encephalopathy Syndrome as Presenting Signs of IgA Vasculitis/Henoch-Schoenlein Purpura—An Educative Case and Systematic Review of the Literature
por: Funken, Dominik, et al.
Publicado: (2021)

Dual intracellular targeting by ruxolitinib and the Mcl-1 inhibitor S63845 in interleukin-6-dependent myeloma cells blocks in vivo tumor growth
por: Burger, Renate, et al.
Publicado: (2021)

IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models
por: Stip, Marjolein C, et al.
Publicado: (2023)

Daratumumab for the Treatment of Multiple Myeloma
por: Plesner, Torben, et al.
Publicado: (2018)

Infection Risk Associated with Daratumumab
por: Johnsrud, Joyce J, et al.
Publicado: (2017)

Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab
por: Abdallah, Nadine, et al.
Publicado: (2022)

Isocitrate dehydrogenase 1 mutation drives leukemogenesis by PDGFRA activation due to insulator disruption in acute myeloid leukemia (AML)
por: Steinhäuser, Sophie, et al.
Publicado: (2022)

Correction: Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab
por: Abdallah, Nadine, et al.
Publicado: (2022)

Daratumumab-induced transient myopic shift
por: Mavrommatis, Maria A., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_1j67336s10pd60aaeuqnansnkf